Others

Haihe Biopharma's Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World's First Oral Paclitaxel Expands into Second Indication in China
3SBioHaihe Biopharma

Haihe Biopharma’s Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World’s First Oral Paclitaxel Expands into Second Indication in China

Shanghai Haihe Biopharma Co., Ltd, a partner of 3SBio Inc. (HKG: 1530), announced that its paclitaxel oral solution (registered trademark: Liporaxel; development code: RMX3001/DHP107), developed in collaboration with South Korea‑based…

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC
ETR: MRKMerck

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC

Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration
Eli LillyNYSE: LLY

Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline
GE HealthcareNASDAQ: GEHC

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline

China’s 11th National Centralized Drug Procurement Draft Unveils Major Pricing & Competition Reforms

China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms

Show More